液体活检在结直肠癌中的研究进展  

Research progress of liquid biopsy in colorectal cancer

作　　者：汪楠 刘静[1] 张俊[1] Wang Nan;Liu Jing;Zhang Jun(Department of Oncology,Ruijin Hospital,Shanghai Jiaotong University School of Medicine,Shanghai 200025,China)

机构地区：[1]上海交通大学医学院附属瑞金医院肿瘤科,上海200025

出　　处：《肿瘤综合治疗电子杂志》2020年第2期7-11,共5页Journal of Multidisciplinary Cancer Management(Electronic Version)

基　　金：国家自然科学基金项目(81972707)。

摘　　要：随着精准医学时代的来临,肿瘤样本的分子表达谱已成为判断预后、制订个体化治疗策略、监测肿瘤复发和耐药的重要依据。相较于组织活检,液体活检技术因其无创性、安全性、全面性和实时动态性等特点,在分子检测领域得到越来越广泛的关注和应用。本文围绕液体活检技术在结直肠癌中的研究进展做一综述,其中包括与组织活检的一致性、早期筛查、监测复发、个体化用药指导和耐药性监测等,并对其局限性和未来发展方向加以展望。In the era of precision medicine,the molecular expression profile of tumors have become more and more important for prognosis,making individualized treatment strategies,and monitoring relapse and drug resistance.Compared with tissue biopsy,liquid biopsy is more widely used in the field of molecular detection due to its non-invasiveness,safety,comprehensiveness,real-time and dynamics.Here we review the research progress of liquid biopsy in colorectal cancer,including consistency with tissue biopsy,early screening,recurrence monitoring,personalized strategies making,and drug-resistance monitoring.Limitation and future development of liquid biopsy are also prospected.

关 键 词：结直肠癌 液体活检 复发 继发性耐药 

分 类 号：R73[医药卫生—肿瘤]